Suspended PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02472002

Mesenchymal Stem Cell Administration in the Treatment of Coronary Graft Disease in Heart Transplant Patients (MESHT)

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions Coronary Disease Heart Transplant

Updated 6 times since 2017 Last updated: Feb 20, 2017 Started: Jan 31, 2014 Primary completion: Jan 31, 2018 Completion: Jan 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

Contamination of the Pitié-Salpêtrière biotherapy laboratory

Listed as NCT02472002, this PHASE1/PHASE2 trial focuses on Coronary Disease and Heart Transplant and remains suspended. Sponsored by Assistance Publique - Hôpitaux de Paris, it has been updated 6 times since 2014, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Suspended PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Suspended PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Suspended PHASE1_PHASE2
May 2017 — Jun 2018 [monthly]

Suspended PHASE1_PHASE2

Status: Recruiting → Suspended

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assistance Publique - Hôpitaux de Paris

Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France